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IT IS COMMONLY ACCEPTED that many
human diseases are due to the action of
environmental factors on individuals with
increased susceptibility. Differences in
individual susceptibilities can be studied
in relation with the antigens coded by the
HLA region. Those antigens play an
important role in self-recognition pro-
cesses, and many of them are strongly
associated with various diseases, as re-
riewed by Dausset (1977). In contrast, the
association with malignant diseases is non-
existent, or at most weak, as in the case
of Hodgkin's disease (Oliver, 1977) and
nasopharyngeal carcinoma (Simons et al.,
1974).
As regards primary liver cancer (PLC),
weak associations have been reported with
A1, by Hammond et al. (1977) in South
Africans, with B12 by Zenvas et al. in
Greece (1979). Individual susceptibilities
to diseases can also be correlated to
genetic markers not coded by the HLA
system; Theodoropoulos et al. (1977), for
example, have found that the Gc2 gene
coding for the corresponding phenotype of
the Ge serum glycoprotein was a risk
factor for PLC without cirrhosis; various
patterns such as serumdeficiency, periodic-
acid-stain-positive and diastase-resistant
globules in hepatocytes of another serum
protein also produced by the liver (the
of -antitrypsin (al-AT)) have been found
by some authors to be associated with
diseases such as chronic obstructive lung
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disease, pulmonary emphysema, juvenile
and adult liver cirrhosis and PLC. al-AT,
a major serum protease inhibitor, can
exist under many genetically coded forms
which can be identified by electrophoresis
techniques in relation to differences of
electric charge. One of those forms, the
MZ phenotype, has been found by Clerc
et al. (1977) to be a risk factor for PLC,
whereas others, such as Charlionet et al.
(1976) and Beaugrand et al. (1978), have
not found such an association. In the
latter group, one can also include Theo-
doropoulos et al. (1976) who, on the other
hand, found a positive correlation between
"FM" (fast moving) (xi-AT components
and PLC.
The discrepancies concerning the asso-
ciation between MZ al-AT and PLC led
us to investigate an African population
consisting of 30 PLC (27 males and 3
females) and 86 controls (65 males and 21
females) hospitalized in Abidjan between
October and December 1978. The controls
included 2 non-hepatic cancers and 84
non-cancer diseases: 32 liver diseases
(cirrhosis, hepatitis, jaundice, abscess of
the liver), 14 people with hepato-spleno-
megaly, 18 with cardiovascular diseases
and 20 miscellaneous cases. Primary liver
cancer cases were established on the basis
of clinical examination plus a-foetoprotein
radioimmunoassay (Sizaret et al., 1975)
and liver biopsy or post mortem. Hepatitis
B virus markers (HBs, anti-HBs, anti-ANTITRYPSIN IN LIVER CANCER 227
TABLE.-aO1 antitrypsin phenotypes and
HBV status in a group of 30 primary
liver cancer (PLC) and 86 other patients
from the Ivory Coast
ot1-AT phenotype
HBV,
Lab. PLC status MI M1M2 M1M3 M2M3
1 - +* 26 1 8 0
- 46 0 5 0
2 - + 25 0 10 0
- 45 0 6 0
land2 + +t 18 4 3 1
- 1 1 2 0
* 23 HBs+ and 12 HBs-, anti HBs Ab-, anti
HBc+.
t All HBs+.
HBc) were assayed by one laboratory
using the Ausria II 125, Ausab and Corab
Abbott kits, and (xi-AT phenotypes were
determined by two laboratories by electro-
focusing in acrylamide gel (Frants et al.,
1978). Before assay all specimens were
aliquoted, and aliquots were coded double-
blind, different codes being used for each
laboratory. Results are indicated in the
Table and.P values have been calculated
using the exact test of Fisher. axl-AT
phenotypes have been expressed according
to the international nomenclature (Cox,
1978). The classical association PLC-
"active infection" by the hepatitis B virus
was apparent, with P< 0.001 and the
relative risk 9-47 (95% confidence inter-
vals=34-26.2). oil-AT assays by two
laboratories gave very close results, since
out of 116 sera analysed there were only
three discrepancies. No MZ phenotype
was found and we think that the different
results reported previously in a similar
population can be both explained by the
use of a different technique (starch gel pH
4.2) and by a different way ofinterpreting
al-AT cathodal fractions commonly ob-
served in PLC patients. Interestingly, the
M2 allele, although not frequent, was
observed mostly in PLC cases, and the
difference from the controls was highly
significant: P=0 0011, relative risk=
21*25 (2.3-988)) for Laboratory 1. The
significance was even greater when results
of Laboratory 2 were used for statistical
analysis, since no M2 allotype was found
among controls. When calculations were
made after matching for HBV status, the
association was still significant in "infec-
ted" persons (P= 0 0456 for Laboratory 1
and 0.0111 for Laboratory 2). but not in
"uninfected" patients, among whom only
one M2 was observed, and it was a case
(P= 0 07 for Laboratory 1 and Laboratory
2).
These results suggest the existence inthe
observed population ofan increased risk of
liver cancer associated with the M2
oil-AT phenotype. That association needs
to be confirmed on a larger group, and it
would also be interesting to examine
whether a similar increased risk exists in
populations from other countries. In that
respect, it is worth bearing in mind that
associations between BW15, B8, B18,
DW3 and/or DW4 ofthe HLA system and
the juvenile diabetes mellitus have been
found in Caucasian population, whereas in
Japan the disease is associated with
BW22, as reviewed by Nerup et al. (1977).
Strengths of association between a
genetic marker and susceptibility to a
disease can be measured by the relative
risk (RR), the confidence interval of
which, in our study, was large. We think
that the hypothetical gene coding for
susceptibility to PLC is notthegene coding
for the M2 phenotype of a1-AT but that
it may be located nearby. The increased
susceptibility to PLC of individuals from
the Ivory Coast having the M2-a1-AT
phenotype seems to be independent of
their HBV status; whether it is related
to an increased sensitivity to aflatoxin,
another agent that is suspected ofa role in
the aetiology ofPLC (Peers et al., 1976), is
unknown.
We are most grateful to Dr C. Chapuis-Cellier
(Service de biochimie clinique, Hopital Edouard
Herriot, Lyon) for her participation in the al-AT
as3ays of serum specimens.
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